# EDGAR Filing Document

**Accession Number:** 0001815436
**File Stem:** 0001213900-23-018669
**Filing Date:** 2023-3
**Character Count:** 55320
**Document Hash:** 5bc61729e20d1db9133db5ec1e3c5fed
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-018669.hdr.sgml**: 20230309

**ACCESSION NUMBER**: 0001213900-23-018669

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 26

**CONFORMED PERIOD OF REPORT**: 20230308

**FILED AS OF DATE**: 20230309

**DATE AS OF CHANGE**: 20230309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Advanced Health Intelligence Ltd
- **CENTRAL INDEX KEY:** 0001815436
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41089
- **FILM NUMBER:** 23718078

**BUSINESS ADDRESS:**
- **STREET 1:** UNIT 5/71 - 73 THE ESPLANADE
- **CITY:** SOUTH PERTH
- **STATE:** C3
- **ZIP:** 6151
- **BUSINESS PHONE:** 61 8 9324 2099

**MAIL ADDRESS:**
- **STREET 1:** UNIT 5/71 - 73 THE ESPLANADE
- **CITY:** SOUTH PERTH
- **STATE:** C3
- **ZIP:** 6151

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Advanced Human Imaging Ltd
- **DATE OF NAME CHANGE:** 20210625

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Advanced Human Imaging, Inc.
- **DATE OF NAME CHANGE:** 20210513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MyFiziq LTD
- **DATE OF NAME CHANGE:** 20200617

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2023

Commission File Number: 001-41089

**Advanced Health Intelligence Ltd**

(Translation of registrant's name into English)

**71-73 South Perth Esplanade, Unit 5**

**South Perth, WA 6151**

**Australia**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

**Note**: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**Note**: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

99.1 [Shareholder Update](ea174874ex99-1_advanced.htm)

99.2 [Company Presentation](ea174874ex99-2_advanced.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | ADVANCED HEALTH INTELLIGENCE LTD | ADVANCED HEALTH INTELLIGENCE LTD | ADVANCED HEALTH INTELLIGENCE LTD |
| Date: March 8, 2023 | By: | /s/ *Scott Montgomery* | /s/ *Scott Montgomery* |
|  |  | Name: | Scott Montgomery |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| **ASX Shareholder Update**<br> **March 8, 2023** | ![](ex99-1_001.jpg) |

---

**SHAREHOLDER UPDATE**

● **Vertica Health acquisition completed.** 

● **wellteq Digital Health acquisition completed.** 

● **AHI team grows from 23 to 61 personnel.** 

● **AHI captures global expertise through key management additions.** 

● **AHI continues to sign new partnerships adding Upvio Healthtech and Augmented Reality Concierge.** 

● **Strategic priorities for 2023 to achieve cashflow breakeven.** 

It is with great pleasure I can address AHI shareholders as CEO for the first time alongside AHI's Founder and Head of Strategy, Vlado Bosanac. Together, we would like to provide an overview of AHI's actions in 2022 whilst many organisations became inactive or paralysed by the ever-descending stress the global financial market imposed. We would like to share the clear focus for 2023 as it's shaping as a pivotal year.

In 2022, with the support of its Board, AHI completed two acquisitions, enabling the company to deliver a biometric health assessment never before available. This new capability addresses a far broader global need in population health screening using its cornerstone intellectual property (IP) as the foundation linking the acquired platforms into a single instance. The year also saw AHI continue to grow its partner base, expand its IP footprint, add to its technology solutions, and grow its team.

As a result, AHI's extended capabilities now offer the following from a user's smartphone:

● **Body dimension** and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates;

● **Blood biomarker prediction**, including HbA1C, HDL, LDL, and 10-year mortality risk;

● **Transdermal Optical Imaging** to return vital signs and cardiovascular disease risk estimates;

● **Dermatological skin i** dentification with 588 skin conditions across 133 categories (Inc. Melanoma); and

● **Personalized health triage empo** wering partners for directional care recommendations and referrals.

AHI's expanded team now totals 61 full-time team members encapsulating a deep understanding of the complexities of the health and care system and the global appetite for convergence and interoperability. This convergence and interoperability are required to reduce cost and introduce remote delivery and scale to facilitate a more efficient and economically sustainable healthcare system to the world.

AHI has developed a smartphone-derived biometric assessment to drive more sophisticated health profiling and better patient outcomes. Its proprietary technology leverages the computational efficiencies on a mobile device, using artificial intelligence, machine learning, and image processing as part of its process to deliver a contactless smartphone-based biometric health assessment.

The assessment takes less than 10 minutes to complete and immediately produces a biometric health report which assists our partners in making triage recommendations for directional care uniquely for each user. This service enables insurers, governments, health and care providers to be at the forefront of the rapidly evolving field of digital health convergence.

Advanced Health Intelligence Ltd.

ACN 602 111 115

Postal Address: PO Box 190, South Perth WA 6951

Email: investors@ahi.tech

---

| | |
|:---|:---|
| **ASX Shareholder Update**<br> **March 8, 2023** | ![](ex99-1_001.jpg) |

---

***A 2023 report by Ark Venture Investment Management LLC stated:***

 ****

*"According to ARK's research, five innovation platforms are converging to create unprecedented growth trajectories. Artificial Intelligence is the most important catalyst, its velocity cascading through all other technologies. The market value of disruptive innovation platforms could scale 40% at an annual rate during this business cycle, from $13 trillion today to $200 trillion by 2030.*

 

*In 2030, the market value associated with disruptive innovation could account for the majority of the global equity market capitalization".*

 

Further reinforcement to this position is the raft of multi-billion-dollar transactions in the healthcare sector, such as Microsoft's acquisition of Nuance in March 2022 for $19.7 billion demonstrating their commitment to data convergence and AI, Oracle's acquisition of Cerner for USD$20 billion and only last week, CVS acquired Oak Street Health for USD$10.6 billion. We speak to this as these organisations are all working toward the delivery of more cost-effective healthcare at scale and the recognition that digital intervention is not only a way to meet the cost and scale needed to deliver more effective care, but it is the only way to deal with growing populations that are living longer and weighing on an already overburdened healthcare system.

Advanced Health Intelligence is well-positioned to supply these and other organisations with similar digital health convergence and interoperability needs. With the completion of the wellteq and Vertica Health acquisitions in 2022, AHI has assembled a team of global leaders, adding immense strength to the AHI team and its unique, proprietary and innovative approach to healthcare and data analytics for the identification of health risks.

Moreover, we expanded the team from 23 to 61 personnel adding internal expertise across healthcare, technology, science, design, sales and finance. The expanded team sees the following industry leaders join AHI to accelerate the company's velocity.

AHI welcomed several key leaders to the company, starting with our newly appointed CEO.

**CEO, Scott Montgomery**. Scott brings two decades of health and care experience, leading two industry companies to exit. Scott co-founded wellteq and led that company to a public exchange listing in Canada ahead of its acquisition by AHI. Mr Montgomery's public company and global industry experience is well suited for AHI's ASX and NASDAQ listings.

**Dylan Garnett** brings 25 years of corporate experience in health, technology, and insurance. The former COO of Zurich Insurance (SA), former CEO of Metropolitan Health Group (SA), and Co- Founder of Vertica Health.

**Riaan Conradie**, AHI's newly appointed Chief Science officer, was a founder of LifeQ, Vertica Health and HealthQ. Riaan combines various fields, including systems biology, electronics, mechanics, mathematics, physics, and computer science, to provide out-of-the-box solutions for cutting-edge technologies in global care, wellness, weight loss and fitness. Riaan's pragmatic approach to rapid testing and development cycles to evaluate and industrialise technology will be a welcome skill to the team as we execute and deliver market-ready digital care under the newly expanded AHI.

**Dr Manie De Klerk** is the newly appointed Clinical Director at AHI. Manie brings decades of experience in medicine, healthcare and technology. Manie is well versed in technology, life sciences and global processes required when organisations such as AHI seek medical approvals throughout the globe such as FDA, TGA or CE. Furthermore, Manie's clinical trialling expertise will see AHI expand its offering to multiple new business opportunities.

Advanced Health Intelligence Ltd.

ACN 602 111 115

Postal Address: PO Box 190, South Perth WA 6951

Email: investors@ahi.tech

---

| | |
|:---|:---|
| **ASX Shareholder Update**<br> **March 8, 2023** | ![](ex99-1_001.jpg) |

---

**Olly Bridge,** AHI's newly appointed Chief Operations Officer, joins AHI from wellteq. Olly brings 25 years of health industry experience. Olly drove the expansion of Global Corporate Challenge (GCC) across over 180 countries prior to joining Medibank, where he was Digital Health lead. Olly has extensive experience working with his teams to drive global sales and expansion.

**Terence Stupple,** Chief Technology Officer at AHI, has been with the company for seven years. Terence brings 20 years of IT leadership and government and MNC technology leadership experience to AHI. Terence has played an instrumental role in the company's technology framework and delivery and assessment of recently acquired technology.

**Kevin Baum,** Chief Product Officer at AHI, brings over 20 years of experience in technology, delivery, and customer success. Kevin has an extensive background in public and private technology companies as a Founder, CEO and MD at Chrome Global, Onsavii, TikForce, and NetSavii; Kevin's role is to lead our product team and ensure product-market-fit for our current and prospective partners.

**Jeames Gillett,** former co-founder of wellteq and AHI's newly appointed Chief Customer Officer. Jeames is an Exercise Physiologist who has spent nearly 20 years working within the Corporate Health and Insurance sectors. A senior leader who has led operations across the full business lifecycle - founding, rapid growth, M&A, and taking a company public. Jeames will ensure our customers receive world-class support to maximise product impact.

**Additional events and matters.**

AHI would like to keep shareholders apprised of events across the ASX and NASDAQ, with further clarity to reassure shareholders that matters are in-hand and any requirements pertaining to the company's compliance requirement on ASX and NASDAQ are being addressed.

**As released to the ASX on February 7, 2023**, Advanced Health Intelligence Ltd (ASX:AHI) (NASDAQ:AHI) (the "Company") was pleased to inform shareholders that the Company had recomplied with the previously announced delinquency notice from NASDAQ and has now lodged the Company's Form 20-F 2022 Annual Report with the United States Securities and Exchange Commission ('SEC'). On November 17, 2022, the NASDAQ Listing Qualification Staff notified the Company that it did not meet the periodic filing requirement for The NASDAQ Stock Market under Listing Rule 5250(c)(1) (the "Rule"). On February 3, 2023, Advanced Health Intelligence Ltd submitted the filing of the Company's Form 20-F 2022 Annual Report with the SEC. Accordingly, NASDAQ Listing Qualification Staff has determined that the Company now complies with the Rule. This matter is now closed.

AHI has broadened the finance team to avoid such delays in the future.

**As released to the ASX on December 22, 2022**, AHI was granted a 180-day extension from the NASDAQ listing Qualification Staff regarding its bid price compliance. Like most listed companies, the company's share price experienced selling pressure over the course of 2022, seeing the share price trade under USD$1.00 for 30 trading days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the bid price for the Company's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days to comply with the rules as set out.

The Company has several options available to it. These options are to trade above USD$1.00 as required, seek approval to reconstruct the shares in the Company to meet the minimum USD$1.00 requirement or delist from NASDAQ. The Company has until the 19th of June 2023 to comply and is doing everything practically possible to meet the requirement and maintain its good standing with NASDAQ and compliance rules.

Importantly, Nasdaq's written notice does not affect the listing or trading of the Company's common stock at this time. The Company will continue evaluating its options to resolve this listing deficiency.

Advanced Health Intelligence Ltd.

ACN 602 111 115

Postal Address: PO Box 190, South Perth WA 6951

Email: investors@ahi.tech

---

| | |
|:---|:---|
| **ASX Shareholder Update**<br> **March 8, 2023** | ![](ex99-1_001.jpg) |

---

**As released to the ASX on the December 1, 2022**, AHI appointed Mr. Montgomery to the Board as the Company's new Chief Executive Officer and Managing Director. Mr. Montgomery has over 20 years of experience in enterprise healthcare around the world, with 15 of those as a founder or director of public and private companies. Mr. Montgomery successfully exited two previous Health companies and is a welcome addition to the AHI team.

**Commercial and funding progress update.**

**As released to the ASX on January 25, 2023**, AHI had concluded formal agreements with Upvio Healthtech.

Upvio offers medical, health and wellness practices powerful technology, including human imaging, feature-rich appointment scheduling, digital forms, video calls, virtual waiting rooms, asynchronous and synchronous chat, a patient portal, and the ability to integrate into any existing software. Upvio enables geo-cloud storage for securely storing sensitive patient information, ensuring that patients' data is always kept safe and secure. Upvio aims to be the first telehealth platform in the world with in-built contactless human imaging tools that can provide a scientifically validated health risk assessment in real-time.

This is a game-changing development, as it means that healthcare professionals can now obtain an accurate picture of a patient's health and risk status more easily, conveniently and affordably without the need for physical contact, drastically reducing the risk of malpractice. The platform is built on a digital-first ethos, with both patients and healthcare professionals in mind and brings together the best- of-breed technologies, including AHI's scanning and risk assessment capabilities.

**As released to the ASX on February 14, 2023,** AHI was pleased to inform shareholders of the signing of the Master Services Agreement (MSA) with US-based Augmented Reality Concierge LLC ("ARC")

Augmented Reality Concierge, LLC (The ARC) is a unique company that builds and implements state- of-the-art applications that empower consumers and companies to simplify and enhance their surroundings whilst improving the lives of their consumers. Using the latest proprietary, innovative technologies, The ARC's creative tools are fun and exciting, allowing people to engage with them to realize their goals. The ARC was created in 2019 to build a fitness application that uses augmented reality navigation to guide users in the gym and show them what to do and how to do it based on each gym's specific equipment range. During this time, the ARC realized that the technology would solve similar problems confronting universities, airports, malls, grocery stores, and theme parks, to mention a few. The ARC then went a step further and designed a true "concierge" concept that caters to a company's or its consumer's wants or needs.

**As released to the ASX on January 30, 2023,** AHI was pleased to inform shareholders that the Company would receive an R&D Grant of A$1,209,334 from the Australian Tax Office. Pleasingly the funds have now been received. In addition to the R&D funding payment, AHI had secured an additional A$1,000,000 short term loan facility to bolster its cash position further. AHI is currently negotiating funding offers it has received from several parties. The facility, along with the R&D reimbursement received, gives AHI ample time to evaluate and finalize funding offers it has received. AHI will keep shareholders informed as these discussions progress.

**<u>AHI's key focuses for 2023.</u>**

Looking forward, the company's overarching objective this year is to achieve cashflow breakeven through the commercialisation of its technology to current and prospective partners. AHI has clear momentum, as outlined above, with its novel technology ready for commercialisation.

Capital market conditions remain uncertain, and so the business strategy is to focus on sound fundamentals and customer-centric practices to reach cashflow breakeven as a priority.

Advanced Health Intelligence Ltd.

ACN 602 111 115

Postal Address: PO Box 190, South Perth WA 6951

Email: investors@ahi.tech

---

| | |
|:---|:---|
| **ASX Shareholder Update**<br> **March 8, 2023** | ![](ex99-1_001.jpg) |

---

To achieve cashflow break-even, we have set the following company priorities:

1) Complete integration – both team and technology to launch the biometric health assessment by March 31, 2023;

2) Deploy updated technology to all existing corporate partners and customers by June 30, 2023; and

3) Validate the recently expanded IP portfolio.

AHI has grown from a headcount of 23 to 61, from a single office location in Perth to eight offices across Singapore, South Africa, Amsterdam, Canada, USA and Australia. A single Company culture for a global team must be achieved in order for us to function in a coordinated service for our commercial partners. Achieving a positive team culture must be a very deliberate project in itself and hence has been the top of our agenda. Pleasingly we are in an operating rhythm that is accommodating all time zones and the first internal release is on schedule for launch in March 2023 as planned. The integrated technology will be demonstrated to our existing commercial partners and additional late- stage prospects from April 2023. AHI's philosophy is to focus our expertise efficiently on productive partners whilst preserving long-term business relationships with those not thriving under current circumstances.

AHI has a valuable patent portfolio with 24 patents across Australia, the USA, Japan, Korea, Singapore, New Zealand, China and Canada. We will continue to invest in deepening our patent position to cover the processes and addition of the recently acquired technologies. Our technology has been widely published in well-respected journals around the world and we will continue to pursue further peer- reviewed publications that provide independent support and validation of our current and new technology and capabilities. We expect to see the first publications in the April-June quarter, which will continue throughout the remainder of 2023.

The completion of both acquisitions in 2022 by AHI has added immense strength to its team of globally recognised industry leaders and assembled unique, proprietary and innovative solutions. The execution by this team of the company's strategy will see AHI help accelerate healthcare's digital transformation and in doing so should provide healthy returns for its shareholders.

With the acquisition of wellteq, I am extremely appreciative to have been appointed CEO and to be part of the strategy implemented throughout 2022 by the AHI team and the Head of Strategy and Founder Vlado Bosanac. We now have a world-class team to execute on our plans in 2023 and beyond. Excitingly, AHI is well-positioned to advance and be a leader in digital health convergence and interoperability.

On behalf of the Board of Directors, Management and the entire team, we thank you for your support and look forward to a year of valuable progress.

Sincerely,

Scott Montgomery,

*Chief Executive Officer.*

 

Advanced Health Intelligence Ltd.

ACN 602 111 115

Postal Address: PO Box 190, South Perth WA 6951

Email: investors@ahi.tech

 

 

---

| | |
|:---|:---|
| **ASX Shareholder Update**<br> **March 8, 2023** | ![](ex99-1_001.jpg) |

---

 

**<u>About Advanced Health Intelligence Ltd</u>**

Advanced Health Intelligence's (AHI) mission is to deliver scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies all over the world via our proprietary technology and processes.

Since 2014, AHI has been delivering Health-tech innovation using smartphones, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, securing and bringing forth the next frontier in digitising healthcare with a suite of componentised solutions.

AHI has assembled a world-class team of machine learning, AI, and computer vision experts along with medically trained data scientists to develop a comprehensive mobile-phone-based risk assessment tool culminating in:

● Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates;

● Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk;

● Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates;

● On-device dermatological skin identification with over 588 skin conditions across 133 categories (including Melanoma); and

● Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically driven triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

For more information, go to www.ahi.tech or contact:

---

| | |
|:---|:---|
| **Scott Montgomery**<br> Chief Executive Officer<br> Advanced Health Intelligence Ltd<br> E: admin@ahi.tech | **Vlado Bosanac**<br> Founder/Head of Strategy<br> Advanced Health Intelligence Ltd<br> E: admin@ahi.tech |

---

The board of Advanced Health Intelligence Ltd has approved this announcement.

Advanced Health Intelligence Ltd.

ACN 602 111 115

Postal Address: PO Box 190, South Perth WA 6951

Email: investors@ahi.tech

## Exhibit 99.2

**Exhibit 99.2**

![](ex99-2_001.jpg)

ASX Announcement March 8, 2023 Advanced Health Intelligence Ltd. ACN 602 111 115 Postal Address: PO Box 190, South Perth WA 6951 Email: investors@ahi.tech Advance Health Intelligence Ltd Company Presentation Advanced Health Intelligence Ltd (ASX:AHI) (NASDAQ:AHI) (the " Company") would like to provide shareholders, and the market with an updated Company presentation. AHI is pleased to release the attached presentation, which includes direction on the Company's mission, technology, pricing structure, business vertical and management team. For more information and access to the new presentation, please visit: www.ahi.tech . For more information, contact: Scott Montgomery Chief Executive Officer Advanced Health Intelligence Ltd E: admin@ahi.tech Vlado Bosanac Founder/Head of Strategy Advanced Health Intelligence Ltd E: admin@ahi.tech The board of Advanced Health Intelligence Ltd has approved this announcement.

![](ex99-2_002.jpg)

Company Overview March 2023

![](ex99-2_003.jpg)

Confidential – Do not duplicate or distribute without the written permission of Advanced Health Intelligence Ltd This presentation ("Presentation") has been prepared by Advanced Health Intelligence Ltd ("Advanced Health Intelligence" or "Company") . You must read and accept the conditions in this notice before considering the information set out in or referred to in this Presentation . If you do not agree, accept or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Advanced Health Intelligence . By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Advanced Health Intelligence from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation . NO OFFER This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law . This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC) . This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares of Advanced Health Intelligence and does not and will not form any part of any contract for the acquisition of shares of Advanced Health Intelligence . SUMMARY INFORMATION This Presentation contains summary information about Advanced Health Intelligence, its subsidiaries and their activities which is current as at the date of this Presentation . The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Advanced Health Intelligence or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act . While Advanced Health Intelligence has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation . NOT INVESTMENT ADVICE Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Advanced Health Intelligence and the impact that different future outcomes may have on Advanced Health Intelligence . This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs . Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction . Advanced Health Intelligence is not licensed to provide financial product advice in respect of Advanced Health Intelligence shares . Cooling off rights do not apply to the acquisition of Advanced Health Intelligence shares. INVESTMENT RISK An investment in Advanced Health Intelligence shares is subject to known and unknown risks, some of which are beyond the control of Advanced Health Intelligence . Advanced Health Intelligence does not guarantee any particular rate of return or the performance of Advanced Health Intelligence nor does it guarantee any particular tax treatment . An investment in Advanced Health Intelligence should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business . FINANCIAL DATA All dollar values in this Presentation are in Australian dollars (A$ or AUD) unless otherwise stated. FORWARD - LOOKING STATEMENTS This Presentation may contain forward looking statements . The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan' and other similar expressions are intended to identify forward - looking statements . Indications of, and guidance on, future earnings and financial position and performance are also forward - looking statements . Forward - looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company . It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements . There can be no assurance that actual outcomes will not differ materially from these statements . You should not place undue reliance on forward - looking statements and neither Advanced Health Intelligence nor any of its directors, employees, advisers or agents assume any obligation to update such information . DISCLAIMER None of Advanced Health Intelligence's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them . To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Advanced Health Intelligence and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise . To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation . Statements made in this Presentation are made only as the date of this Presentation . The information in this Presentation remains subject to change without notice .

![](ex99-2_004.jpg)

Corporate overview Advanced Health Intelligence (ASX - NASDAQ.AHI) is a global digital health solution. • AHI sells its dHaaS (digital health - as - a - service) technology to enterprise, healthcare, insurance and government customer segments around the world in a business - to - business model (B - to - B) . • AHI completed two acquisitions in 2022 , expanding its capabilities to offer end - to - end digital health services from mass population health engagement and loyalty to diagnostics, all from a user's smartphone . • AHI holds patents in Australia, USA, Japan, Korea, Singapore, New Zealand, China and Canada and expects to add to the patent portfolio . • AHI screens for health risk stratification from a smartphone camera by capturing biometric data, including vital signs, body composition, dimension, and indicative blood markers . In addition, AHI offers DermaScan which covers 588 skin conditions across 133 categories . • AHI technology partners use AHI technology to assess risk profiles targeting physical activity, mental health, sleep and nutrition coaching . AHI's technology is 100 % algorithmic, no people required . • Based on identified health risk makers, AHI empowers its partners to triage its users into its stepped care model to either sub - clinical e - health programs or escalate to primary care, including telehealth . Early detection and intervention provides ROI to many payors . Advanced Health Intelligence (ASX/NASDAQ . AHI) is a global digital health solution Investor presentation - March 2023 3 Issuer Advanced health intelligence Ltd Exchange Australian Stock Exchange (ASX) & Nasdaq Capital Market (NASDAQ) Shares on issue As at 1 March 2023 196,053,969 including ADR cover Employee headcount\* 61, across Australia, Singapore, USA, Canada, South Africa, Netherlands. Current partners addressable audience > 400 million addressable users across AHI's current partners Intellectual property 24 patents, across Australia, USA, Japan, Korea, Singapore, New Zealand, China And Canada

![](ex99-2_005.jpg)

On a mission to create ubiquitous proactive healthcare Advanced Health Intelligence (AHI) delivers scalable health assessment, risk stratification and introduces the ability to digitally triage users for healthcare providers, insurers, employers and governments . Since 2014 , AHI has been delivering health - tech innovation using a smartphone, starting with the world's first on - device body dimensioning capability . AHI has developed further IP and been issued patents bringing forth the next frontier in digitizing healthcare with a suite of componentized solutions culminating in : • Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates . • Blood biomarker prediction , including HbA 1 C, HDL, LDL, and 10 - year mortality risk . • Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates. • Dermatological skin i dentification with over 588 skin conditions across 133 categories (Inc. Melanoma). • Personalised nudges for e - health coaching and programs assisting partners in delivering personalised therapeutic and non - therapeutic e - health programs to improve daily habits and build health literacy. The delivery of these proprietary capabilities ushers forth an era of cost - effective health accessibility for billions of smartphone users worldwide . In doing so, AHI endeavours to put the power of proactive healthcare in the hands of communities, empowering people to take control of their own journey to better health outcomes . Scott Montgomery Vlado Bosanac Chief Executive Officer Founder / Head of Strategy Investor presentation - March 2023 4

![](ex99-2_006.jpg)

AHI has assembled a world - first for smartphone driven biometric health solutions +BodyScan +FaceScan +Body Composition +DermaScan + Biometric health risk assessment + Blood biomarker prediction, including HbA1C, HDL, LDL, + Directionalized care Integration Ubiquitous proactive healthcare ADVANCED HUMAN IMAGING Investor presentation - March 2023 5 ACQUISITION VERTICA HEALTH ACQUISITION WELLTEQ DIGITAL HEALTH AHI NEW SOLUTION NOW

![](ex99-2_007.jpg)

Unlocking the pipeline The acquisitions of Vertica Health and Wellteq Digital Health Inc. have concluded. Following the technology integration, AHI can now offer a full - service platform. The expanded offering opens up additional customer segments for a larger total addressable market. AHI expects to release the full - service platform in Q2 - 2023, AHI has commenced marketing the expanding solution to the customer pipeline and existing partners. AHI delivers a unique portfolio, unmatched in the market. Investor presentation - March 2023 6

![](ex99-2_008.jpg)

The world's largest companies are investing to improve healthcare 7 AHI's capabilities are able to augment these partners and their solutions. The magic is what happens when you bring them all together, when you use technologies to surround the patients in their reality on a regular basis . The way to achieve this 'omnipresence' is to use automation to move beyond the usual supply and demand constraints in healthcare" Roy Schoenberg, CO - CEO AMWELL on his $320m acquisitions of SilverCloud and Conversa 1 ACQUISITION ($943/USER) US $20B completed Jun 2022 ACQUISITION ($72/USER) US $2.1B completed Jan 2021 ACQUISITION ($5400/USER) US $2.8B completed Jul 2022 ACQUISITION US $19.7B completed Mar 2022 ACQUISITION UNDISCLOSED Launched May 2022 ACQUISITION UNDISCLOSED completed Nov 2021 ACQUISITION (EST. $1B) UNDISCLOSED completed Jun 2022 ACQUISITION US $18.5B completed Oct 2020 ACQUISITION US $1.5B announced Aug 2022 Investor presentation - March 2023 ts%20in%202021&text=With%20another%20start%20to%20a,3%20million%20users%20each%20day. https:// www.franciscopartners.com/news/francisco - partners - completes - acquisition - of - ibm - s - healthcare - data - and - analytics - assets - launches - healthcare - data - company - mirative Sources:https:// www.cerner.com/newsroom/cerner - client - contracts - 2021#:~:text=Contact%20Us - Francisco Partners = $30b AUM. ,Growth%20Report%3A%20Cerner%20Adds%2C%20Extends%2C%20Expands%20More%20Than,400%20Client%20Contrac https://newsroom.ibm.com/2022 - 01 - 21 - Francisco - Partners - to - Acquire - IBMs - Healthcare - Data - and - Analytics - Assets https:// www.fiercehealthcare.com/tech/google - closes - 2 - 1b - acquisition - fitbit - as - justice - department - probe - continues https:// www.healthcaredive.com/news/cvs - microsoft - alliance - digital - health/610850/ https://corporate.walmart.com/newsroom/2021/05/06/walmart - health - to - acquire - telehealth - provider - memd

![](ex99-2_009.jpg)

Global traction 8 • AHI's current clients have an available audience of over 400 million potential users. • Our origins in the Asia Pacific region have produced multicultural capabilities and traction in the world's most diverse market – a perfect launchpad for global distribution. • Some partners, past and present, that trust AHI's team with their digital health offering. 48 % Participants improved mood n= 273, 11 countries 54 % Less stress at work n= 273, 11 Countries 70% Participants improve their deep sleep n= 273, 11 Countries 38 minutes More sleep each night n= 529, 8 APAC countries Reduced alcohol intake n= 273, 11 countries 42% Average reduction in daily added sugar consumption n= 282, 14 countries 64 % Company participation n= 666, Singapore 2.2 % Waist - hip ratio reduction n= 666, Singapore Proven results produced by AHI's current and acquired technologies Investor presentation - March 2023 \*The statistics outlined are from various customer engagements performed by the Company

![](ex99-2_010.jpg)

The triple aim of healthcare 9 This framework was developed by the Institute of Healthcare Improvement (IMI) to optimize healthcare system performance Better population health Better patient experience Lower per capita cost Investor presentation - March 2023 Source: https:// www.ihi.org/Engage/Initiatives/TripleAim/Pages/default.aspx

![](ex99-2_011.jpg)

Integrated stepped care at scale 10 We believe that a stepped care model that deploys our suite of healthcare components is the key to providing truly accessible and scalable healthcare screening . Targeted digital interventions Personalized eHealth programs for targeted outcomes (i.e. the opposite of one - size - fits - all public health). Telehealth or physician consultation for condition management Where clinically appropriate, refer into telehealth and physician clinics. SUB - CLINICAL CLINCAL 01 Population health screening and engagement Leverage low - cost digital wellbeing to connect with entire populations. Assist health professionals by triaging large population data sets into personalized care plans. 02 03 Continuum of care Very low cost per person Entire population Very low cost per person People identified as high risk of selected illness Varies by provider Peoplee diagnosed with selected illnesses Investor presentation - March 2023 Sources: https:// www.mckinsey.com/capabilities/mckinsey - digital/our - insights/health - systems - improving - and - sustaining - quality - through - digital - transformation https:// www.digitalauthority.me/resources/state - of - digital - transformation - healthcare/ AHI Literature review

![](ex99-2_012.jpg)

Components of digital healthcare AHI technology extends its partners digital health capabilities to meet their global needs through five components. These five components introduce healthcare ubiquity via a smartphone Investor presentation - March 2023 Global patents Biometric scans • 24 / 7 accessible health biometrics & assessment from your smartphone camera • Body fat %, waist & hip circumference, blood pressure, blood lipids, blood glucose, + more • Dermatology diagnosis for 588 skin conditions (incl melanoma) 24/7 health screening • Risk stratify health morbidity and mortality from biometric assessments • Insurance underwriting assessment Personalized eHealth • E - Health programs to coach weight management, sleep, mental health and improve general health literacy. • Selected programs expected to become digital therapeutics in 2023/4 Triage into primary - care • Triage low - moderate risk into e - health programs • Refer high risk into telehealth, GP clinics or specialty consultation. Analytics portal • Epidemiology Analytics • Administrator portal • Composable microservices architecture 11

![](ex99-2_013.jpg)

Smartphone Biometrics BodyScan Body circumference, body composition, health indicators, health risks. Health Risks Obesity T2 Diabetes 2 Metabolic Syndrome 1 Central Obesity Body Composition Total Body Fat Waist - Height Risk Indicators Waist - Hip BMR FFM LBM Circumference Chest Waist Thigh Hips Accuracy, Validation 3 97.5% AVG ACCURACY 98% REPEATABILITY 1. Available by combining a Face Scan and BodyScan data, or supplying Blood Pressure. 2. Available by combining self - reported information. 3. Both accuracy and repeatability have been validated by Professor Timothy Ackland, Professor of Applied.Anatomy and Biomechanics, The University of Western Australia – ASX Announcement 18/10/2018. FaceScan Vital signs, cardiovascular health indicators, and health risks. 1. Reference Device: Biopac Systems, ECG, 3 - leads. Biopac respiration module with pneumatic belt. Biopac with continuous BP module, and Nurse using Auscultation Method. Framingham Study for risk prediction. Health Risks CVD Heart Attack Stroke Vital Signs Heart Rate Blood Pressure Respiratory Rate Cardiac Workload Health Indicators IHB HRV Hypertension Hypotension Accuracy, Validation 1 99% HEART RATE 95% BLOOD PRESSURE 98% REPEATABILITY DermaScan Œ Skin disease detection for over 500 skin conditions, . Validation Weight Prediction 1. "Triage vs. USA Board - Certified Physicians", Company Overview September 2020 Compliance Skin Conditions 588 Conditions Acne Dermatitis Insect bites Carcinoma Melanoma Shingles Eczema Warts Psoriasis … Software as a Medical Device (Canada) Blood Biomarkers Blood estimates and health risk indicators. Accuracy, Validation A scientifically proven systems biology approach is used to provide accurate estimates with a day - to - day estimate variability margin that aligns with traditional blood tests. Validation studies are in process Validation studies are in process. C - Reactive Protein Blood Estimates Triglycerides Total Cholesterol HDL Cholesterol LDL Cholesterol Health Indicators Hypercholesterolemia Insulin Resistance Inflammation 12

![](ex99-2_014.jpg)

Engaged customers Our current partners represent a total addressable audience of over 400 million people. A 2% adoption rate with current partner audiences would drive AHI to profitability. 1,000,000 From £3.49 user/mo 1,000,000 From $3.57 user/mo TBC TBC user/mo 400,000 From US$3.49 user/mo 100,000 US$4,100,000 \* 1,000,000 From US$2.00 user/mo 1,160,000 US$1.50 user/mo 100,000 From $TBC user/mo 1,000,000 From US$2.99 user/mo 200,000 From $TBC user/mo 20,000 From US$4.99 user/mo TBC From US$4.99 user/mo 100,000 From US$4.00/pa 1,000 From US$4.00 user/mo 5,000 From $TBC user/mo 10,000 From $2.00 user/mo 100,000 From US$27.00 user/mo PARTIAL LAUNCH 4.7m Total targeted users FULL LAUNCH .01m Total targeted users PRE LAUNCH 2.6m Total targeted users 100,000 From $TBC user/mo 13 Investor presentation - March 2023

![](ex99-2_015.jpg)

Distribution partners and pricing Industry Segment Enterprise Customer (Payor) Pricing / user /month. Enterprise Health Corporate Health Group insurance $2 - $6/month Population Health Health & Life insurance Healthcare provider Government NGO's $1 - $2/month Digital Therapeutics Government Health & Life Insurer $30/month (therapeutics) DISTRIBUTON PARTNERS AHI deploy an enterprise digital - health - as - a - Service (dHaaS) pricing model PRICING 14 Investor presentation - March 2023

![](ex99-2_016.jpg)

Addressable markets 15 Investor presentation - March 2023 Enterprise $58B industry 7% CAGR Health and life insurance $5T industry, 3% CAGR Healthcare providers $11T industry 9% CAGR Government healthcare and philanthropy funds $16T industry 9% CAGR Payor ROI – why they buy dHaaS: 1. Reduced cost and risk (through early detection and intervention opportunities) 2. Improved health and care outcomes 3. Process automation (HR, health care providers) 4. Data – better understand customer needs, improving sales of core goods/services better 62% of smartphone users use their phone for mHealth. A more common smartphone activity than online banking (57%), job searches (42%). Scalable screening capabilities to support acute population screening or responses to health crises such as Monkeypox. Source: 1. https:// www.globenewswire.com/en/news - release/2022/04/11/2420173/0/en/Worldwide - 3 - Trillion - Health - Insurance - Market - Size - is - Expected - to - Grow - at - a - CAGR - of - over - 4 - 4 - During - 2022 - 2028 - Vantage - Market - Research.htm l 2. https:// www.mordorintelligence.com/industry - reports/global - life - and - non - life - insurance - market -- growth - trends - and - forecast - 2020 --- 2025 3. https:// www.businesswire.com/news/home/20190625005862/en/The - 11.9 - Trillion - Global - Healthcare - Market - Key - Opportunities - Strategies - 2014 - 2022 --- ResearchAndMarkets.com 4. https://stats.oecd.org/Index.aspx?DataSetCode=SHA 5. https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC4695957/

![](ex99-2_017.jpg)

Multi - market growth strategy STAGE 5: Government Healthcare Connected patient for Virtual Care STAGE 3: Targeted Interventions Industrial health & safety, chronic illness, mental health & weight loss STAGE 4: Primary Care Subclinical applications into primary care & Wellness real world evidence STAGE 2: Insurers Improve insurance customer acquisition, engagement, and claims ratio (profitability) STAGE 1: Enterprise Protect people and pro ﬁ ts - reduce absenteeism, sta ﬀ turnover, insurance claims AC Q U IS IT IO N & L I C E N S I NG ST RA T E G Y to accelerate geographic footprint and multilingual health program development STAGE 6: Ubiquitous proactive healthcare Rationale Stage 1 Opens new geographical markets through Enterprises Stage 2 Introduces risk payor and mass population distribution Stage 3 Refines programs for health outcomes in high risk users that will become digital therapeutics Stage 4 Opens primary care relationships Stage 5 Introduces the largest market payor Priorities 1 Expand adoption in existing geographical markets 2 Open new geographical markets 3 Certify ﬁ rst targeted program as digital therapeutic 16 Investor presentation - March 2023

![](ex99-2_018.jpg)

Advanced Health Intelligence is a health technology company that provides automated digital health solutions globally. Mission Provide proactive, personalized healthcare to every smartphone user globally. Vision Ubiquitous proactive healthcare. 17 Investor presentation - March 2023

![](ex99-2_019.jpg)

Company highlights • Robust commercial network : Current agreements include 31 active Partnerships targeting users from an available audience of over 400 m • Large addressable market across 4 business verticals. • Cutting edge innovative and proprietary technology in a Global and fast - growing industry • B - to - B Business model enabling rapid growth and scalability through existing and growing networks • Experienced management team with a successful track record Global patents 18 Investor presentation - March 2023

![](ex99-2_020.jpg)

Board and management data 19 Investor presentation - March 2023 Nick Prosser CHAIRMAN • 15+ years ICT experience. • Founder of $1.16 billion centre exit in 2016 Mike Melby INDEPENDENT DIRECTOR • Founder of ﬁ ntech exit to Phunware • Investment banker and private equity investor Scott Montgomery CEO / DIRECTOR • 20 years industry experience • 2 B2B health industry exits, APAC Peter Goldstein INDEPENDENT DIRECTOR • 30 years capital market, M&A , advisory experience • Founder of Exchange Listing, LLC. CEO of Grandview Capital Partners, Inc. Dr Katherine Iscoe EXECUTIVE DIRECTOR • PhD in medical technology • MSc Exercise Physiology & Endocrinology • BA with Honours, Kinesiology & Exercise Science. Dato Low Koon Pow INDEPENDENT DIRECTOR • 20 years accounting and corporate finance experience. • Executive Director SGX company. Vlado Bosanac FOUNDER / HEAD OF STRATEGY • 30 years capital market, investment banking and Board of Directors experience • 4 exits (Health & Technology) • Founder AHI Olly Bridge COO • 25 years of health industry experience, • Former digital health lead at Australia's largest insurer technology Terence Stupple CTO • 20 years IT leadership • Government, MNC leadership. • AHI CTO 7 years Dylan Garnett CIO • 25 years corporate experience • Former COO Zurich Insurance (SA), Former CEO Metropolitan Health Group Simon Durack CFO • 30+ years CPA • 20+ years Board experience Jacqueline Yee INDEPENDENT DIRECTOR • 30 years institutional investor & global capital markets structured finance experience > $25 B • Board Directorships UK and APAC • Funderbeam Exchange CEO

![](ex99-2_021.jpg)

Research - led, science backed and published globally DXA reference values and anthropometric screening for visceral obesity in Western Australian adults. 20 Investor presentation - March 2023 Obesity and visceral fat in Indonesia; An unseen epidemic? A study using iDXA and surrogate anthropometric measures. Smartphone derived body composition and anthropometry for tracking weight loss Arti ﬁ cial Intelligence in the Evaluation of Telemedicine Dermatology Patients Longitudinal concordance of body composition and anthropometric assessment by a novel smartphone application across a 12 - week self - managed weight loss intervention The Hidden Public Health Problem of Inadequate Sleep: Deploying Digital Mobile Technology to Improve Employee Sleep Hygiene in Asia The research and studies associated with the efficacy of our technologies has been featured in luminary publications. BODYSCAN Agreement of anthropometric and body composition measures predicted from 2D smartphone images and body impedance scales with criterion methods BODYSCAN BODYSCAN BODYSCAN DERMASCAN BODYSCAN E - HEALTH PROGRAM E - HEALTH PROGRAM BODYSCAN E - HEALTH PROGRAM High Impact Employee Stress Reduction and Wellness Promotion Delivered via Digital Mobile Technology in the Construction and Aviation Industries No retrenchment from employee empowerment Employer wellness imperatives and opportunities emerging from the COVID - 19 pandemic. Employee Wellness in a Changing Climate: Environmental Heat Stress Driving Need for Targeted Health Promotion and Risk Reduction COVID Contextual wellness in the age of COVID - 19: Managing disproportionate pandemic anxiety and stress in Australia, Singapore and other nations achieving disease control success. Superiority of Artificial Intelligence in the Diagnostic Performance of Malignant Melanoma Compared to Dermatologists and Primary Care Providers DERMASCAN

![](ex99-2_022.jpg)

Thank - you For more information on how Advanced Health Intelligence, find out more at https://ahi.tech Corporate Headquarters Suite 5 , 71 - 73 South Perth Esplanade, South Perth WA 6151 hello@ahi.tech Other locations / Asia Pacific: Perth, Melbourne, Sydney, Singapore North America: Vancouver, Denver South Africa: Cape Town Europe: Amsterdam© 2023 Advanced Health Intelligence Ltd. All other trademarks are property of their respective owners. Scott Montgomery Chief Executive Officer / Director +65 8456 3858 scott.montgomery@ahi.tech Vlado Bosanac Founder / Head of Strategy +61 412 000 409 vlado.bosanac@ahi.tech